Spiritus Mundi Share Discussion Threads

[hedgehog 100] 06/3/2024 15:27

06/03/2024 13:08 RNS Regulatory News Spiritus Mundi PLC Proposed Acquisition and Suspension of Listing LSE:SPMU Spiritus Mundi Plc

"Spiritus Mundi plc, (LSE:SPMU), the Special Purpose Acquisition Company (SPAC) seeking to acquire targets in Europe and Asia in the clinical diagnostics sector, is pleased to announce that it has entered into a heads of terms (the "Head of Terms") to acquire the entire issued share capital of InReste Pte. Ltd. ("InReste") (the "Proposed Acquisition"). The Proposed Acquisition would constitute a reverse takeover under the UK Financial Conduct Authority ("FCA")'s Listing Rules.

InReste operates in the healthcare sector, offering a range of innovative technologies and solutions, including through its related companies. It is an integrated healthcare and wellness provider with an established biomedical research and development arm that holds exclusive patents over a number of clinical diagnostic tests. InReste is currently in the process of undertaking a corporate reorganisation such that, prior to entering into the Proposed Acquisition, it will own the entire issued share capital of Restalyst Pte. Ltd. ("Restalyst") and Reste Laboratories Pte. Ltd. ("ResteLab") (the "Restructuring"). ResteLab operates a 20,000 square foot state-of-the-art laboratory in central Singapore, offering a comprehensive selection of testing, screening and laboratory services to clinicians and healthcare professionals. It is automated to process laboratory tests quickly, turning around up to 10,000 tests daily. These services are complemented by Restalyst, which is an innovative biomedical company that develops, manufactures and markets a range of diagnostic solutions. It provides clinically-proven diagnostic solutions, including a number of patented solutions, to the medical and healthcare industry including detection kits for gastric cancer, nasopharyngeal (nose) cancer and liver cancer.

Zaccheus Peh, the Company's Non-Executive Chairman, is a controlling shareholder of InReste and is expected to hold a controlling interest in InReste following completion of the Restructuring. ..."




SPMU has been suspended today at a share price of 3.75p, market cap. £2.22M.

And as at 30 September 2023 the Company held £498,626 in cash.

[tomboyb] 18/7/2023 06:50

more dir deals -

[tomboyb] 14/7/2023 06:49

v illiquid -

hence the spread -

[tomboyb] 14/7/2023 06:33

More Dir buying -

[tomboyb] 13/7/2023 13:03

v low stock -

[tomboyb] 13/7/2023 09:01

Shell and investing companies having a bit of a renaissance -

[yohoho] 13/7/2023 08:52

more buying this morning.

[tomboyb] 13/7/2023 08:35

More dir buying -

RNS -

[tomboyb] 13/7/2023 06:57

Shell time! -

[hedgehog 100] 12/7/2023 19:10

LSE % Gainers
Top Lists
EPIC Name %
IIG Intuitive Investm... +68%
SPMU Spiritus Mundi +43%


Thanks Tomboyb.

Today's top two risers are an investment company (IIG) & a shell (SPMU).


There are some great value shells around at the moment.

And ARA looks like the best current opportunity:-

"Aura Renewable Acquisitions: Small Shell, Big Ambitions"


ARA: 5.75p, market cap. £603,750.; cash 31.12.22 £809K.

SPMU: 5p, market cap. £2.47M.; cash 31.3.23 £739,812.

[tomboyb] 12/7/2023 14:26

up 42% -

Shell time following iig -

[tomboyb] 11/7/2023 09:56

could climb 5p+ -

[hedgehog 100] 26/2/2023 13:07

Current share price 26th. February 2023: 1.75p
49,300,000 shares in issue
Market capitalisation: £862,750.


"About Us

Spiritus Mundi plc is a Special Purpose Acquisition Company (SPAC) incorporated in the United Kingdom. Our mission is to identify and partner with business that complements the experience and skills of our management team to build out investments in close alignment of our acquisition target in healthcare industry.

The Company is a newly formed entity established to seek acquisition opportunities in the Healthcare services sector focusing primarily on pathology and laboratory testing, clinical diagnostics, and digital health.

Together, the Directors have many years of business experience of operating in the healthcare and financial services industry, particularly in the areas of clinical diagnostic laboratory services, acquisitions, capital markets and trading and they have established a network of contacts internationally within the sector. The Company will utilise independent third parties to provide expert advice where necessary."




08/07/2022 06:00 UK Regulatory (RNS & others) Spiritus Mundi PLC Admission to trading on the London Stock Exchange LSE:SPMU Spiritus Mundi Plc

"Spiritus Mundi plc ("Spiritus Mundi" or the "Company"), a Special Purpose Acquisition Company (SPAC) which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector, is pleased to announce that at 8:00 a.m. today its entire issued ordinary share capital, consisting of 49,300,000 ordinary shares, will be admitted to the Standard Listing segment of the Official List of the Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange ("Admission") under the ticker "SPMU" and ISIN GB00BMHR3L94.

Spiritus Mundi was established in 2021 by Zaccheus Peh, an experienced developer of clinical diagnostics, laboratory services and medical services businesses, as a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector to include (but not limited to):

-- Clinical laboratory services (clinical lab);
-- Clinical Diagnostics (PCR and blood test); and
-- Digital Health (Healthcare IT platform).

The Company's board, detailed in the appendix below, through their established global network of contacts, have identified a number of potentially promising acquisitions. The Company does not currently have any specific initial acquisition under consideration.

The Company will seek to create an attractive income-generating business and increase shareholder value through the operation of the acquired business or businesses.

The board will be focussed on the identification and acquisition of companies which have one or more of the following characteristics:

-- are run by a management team with a strong track record of generating growth for shareholders and a proven experienced business record;
-- have attractive commercial prospects within the clinical diagnostics sector in general;
-- will have the capability to further develop their activities in a post Covid world; and
-- have revenues which offer the potential for near-term positive cash flows.

An acquisition (and potentially, any subsequent acquisitions or investments made by the Company) is likely to be treated as a reverse takeover for the purposes of Chapter 5 of the Listing Rules and the Company will need to seek re-admission of Spiritus Mundi and its acquired subsidiaries to listing on the Official List and trading on the London Stock Exchange or to another stock exchange. Subsequent acquisitions may also be treated as reverse takeovers depending on their size and nature. Additional funding may be needed in the future to acquire further business and provide working capital.

Zaccheus Peh, Non-Executive Chairman of Spiritus Mundi, said: "I am delighted that Spiritus Mundi is listing on the London Stock Exchange. We believe there are attractive acquisition opportunities in our chosen sectors of laboratory and diagnostic testing, and digital healthcare, particularly in light of how the COVID -19 pandemic has changed the sector dynamics. We plan to use Spiritus Mundi as a vehicle to acquire one or more exciting businesses in these areas in order to generate attractive returns for our shareholders."

Total Voting Rights

Following Admission total number of Ordinary Shares with voting rights in the Company is 49,300,000. The Company does not hold any shares in treasury and all of the ordinary shares have equal voting rights. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Prospectus

The Company's Prospectus was published on 30 June 2022 and is available to view on the Company's website: www.spiritusmundiplc.com

For further information please contact:

Spiritus Mundi plc Via IFC
Zaccheus Peh (Non-Executive Chairman)
VSA Capital (Financial Adviser) [phone]
Andrew Raca, Pascal Wiese [e-mail]
Stanford Capital Partners (Broker)
Patrick Claridge / John Howes [phone]
IFC Advisory Limited (Financial PR
and IR) [phone]
Tim Metcalfe, Florence Chandler [e-mail] ..."




From Spiritus Mundi's prospectus dated 30th. June 2022:-

"On 28 April 2021, the Company undertook the Founder Subscription round to raise gross proceeds of £50,000 at a price of £0.01.
On 12 July 2021, the Company completed the Friends & Family Subscription round to raise gross proceeds of £1,161,000 at a price of £0.03.
On 26 April 2022, the Company completed the Subscription to raise gross proceeds of £280,000 at a price of £0.05.
Following the Subscription, the Company will have 49,300,000 Ordinary Shares in issue. The Subscription Shares will rank pari passu with the Existing Ordinary Shares."